# Eslicarbazepine Acetate (BIA 2-093) as Monotherapy in Patients With Newly Diagnosed Partial-onset Seizures

> **NCT02484001** · PHASE3 · COMPLETED · sponsor: **Bial - Portela C S.A.** · enrollment: 206 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** ESL 800 mg
- **DRUG:** ESL 1200 mg
- **DRUG:** ESL 1600 mg
- **DRUG:** ESL 400 mg

## Key facts

- **NCT ID:** NCT02484001
- **Lead sponsor:** Bial - Portela C S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-01
- **Primary completion:** 2018-09-11
- **Final completion:** 2018-09-11
- **Target enrollment:** 206 (ACTUAL)
- **Last updated:** 2018-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02484001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02484001, "Eslicarbazepine Acetate (BIA 2-093) as Monotherapy in Patients With Newly Diagnosed Partial-onset Seizures". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02484001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*